A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel chimeric antigen receptor‐T cell therapy in Southeast and South Asia-Reference-Cited by-同舟云学术

A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel chimeric antigen receptor‐T cell therapy in Southeast and South Asia

Published:2022-08-15 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Lim Francesca Lorraine Wei Inng¹^ORCID,Yunxin Chen¹,Huang Feng‐Ju²,Khee Hwang William Ying¹

Affiliation:

1. Singapore General Hospital Singapore Singapore

2. Novartis Singapore Pty Ltd. Singapore Singapore

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3057

Reference35 articles.

1. CAR T‐cell therapy for relapsed/refractory non‐Hodgkin's lymphoma: a comprehensive review;St‐Pierre F;Clin Adv Hematol Oncol,2022

2. Improving outcomes and mitigating costs associated with CAR T‐cell therapy;Borgert R;Am J Manag Care,2021

3. Transnational medical travel: patient mobility, shifting health system entitlements and attachments

4. Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design;BMJ Open;2024-01